This unique initiative unites charity, academic and private sectors in the search for new dementia treatments.
The Dementia Consortium is a partnership programme between Alzheimer’s Research UK, LifeArc and the pharmaceutical companies, Abbvie, Astex, Eisai, Lilly and MSD.
This initiative encourages applications from researchers across the world, teaming them up with UK-based drug discovery teams to develop their research findings into new treatments. This global initiative runs in tandem with the UK-based Drug Discovery Alliance, making sure we leave no stone unturned in our search for new treatments. You can read more about the Dementia Consortium on our blog or at www.dementiaconsortium.org.
By sustaining a healthy pipeline of potential new drugs for dementia, we will increase the likelihood of findings successful treatments that can transform lives. Our Global Clinical Trials Fund is positioned to make sure that potential new dementia treatments being developed through our drug discovery work have the opportunity to go into clinical testing in people – the final stage on the road to a new medicine.